ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
SPDR S&P Biotech ETF
156.20
-0.6200
-0.40%
盤後：
156.43
0.2300
+0.15%
19:59 EDT
成交量：
841.39萬
成交額：
13.25億
市值：
105.24億
市盈率：
8.57
高：
159.66
開：
158.27
低：
156.13
收：
156.82
52周最高：
169.89
52周最低：
92.64
股本：
6,737.50萬
流通股本：
6,737.50萬
量比：
1.28
換手率：
12.49%
股息：
0.56
股息率：
0.36%
每股收益(TTM):
18.23
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞
公告
北京生物醫藥保險共保體正式成立 完善創新醫藥產業保障
央视新闻客户端
·
09/09
醫療保健板塊動態：市場快訊綜述
投资观察
·
09/09
美股收盤：三大指數集體下跌，道指跳水重挫超600點；半導體、光通信逆市狂飆，英特爾升逾9%，Lumentum升逾11%；生物醫藥齊跌，科技普跌
中新经纬
·
09/09
醫療保健板塊快訊：市場動態一覽
投资观察
·
09/09
摩根士丹利：Grindr醫療健康業務藴藏巨大商機
投资观察
·
09/09
醫療保健板塊動態匯總：市場快訊
投资观察
·
09/09
Tenet Healthcare（THC）擬私募發行15億美元票據，置換到期債務
金吾财讯
·
09/08
HCW Biologics與Akron Biotech簽署獨家分銷協議，將HCW11-006作為試劑商業化，用於支持高功
智通财经
·
09/08
大家人壽9.8億元投資接力基金 後者投向硬科技、醫療健康等領域
智通财经
·
09/08
泰達生物(08189)與星辰通用簽署戰略合作框架協議 共同推動醫療健康具身智能技術體系、產品體系和解決方案的形成與產業化落地
智通财经
·
09/08
英國藥品和醫療保健產品監管局已受理Biosplice公司關於洛雷西文特治療膝骨關節炎的申請，並正式啓動評估程序。
智通财经
·
09/08
醫療保健板塊市場快訊匯總
投资观察
·
09/08
港股生物醫藥股午後走強，劑泰科技-P漲近15%，百奧賽圖-B、金斯瑞生物科技漲近10%
老虎资讯综合
·
09/08
醫療保健板塊動態：市場快訊匯總
投资观察
·
09/08
醫療保健板塊市場快訊匯總
投资观察
·
09/08
2070元/月，佛山這筆錢上調
珠江时报
·
09/07
醫療健康板塊動態：市場快訊匯總
投资观察
·
09/07
從美妝到生物科技公司 植物醫生挺進大健康領域
同花顺
·
09/07
人保健康保險大連分公司被罰27萬，涉聘任不合格人員等
蓝鲸财经
·
09/07
醫療健康板塊動態：市場快訊匯總
投资观察
·
09/05
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/XBI/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"XBI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","market":"US","secType":"STK","nameCN":"SPDR S&P Biotech ETF","latestPrice":156.2,"timestamp":1789156800000,"preClose":156.82,"halted":0,"volume":8413893,"hourTrading":{"tag":"盘后","latestPrice":156.43,"preClose":156.2,"latestTime":"19:59 EDT","volume":555911,"amount":86836947.7522,"timestamp":1789171191129,"change":0.23,"changeRate":0.001472,"amplitude":0.001601},"delay":0,"changeRate":-0.0039535773498278574,"floatShares":67375000,"shares":67375000,"eps":18.23,"marketStatus":"休市中","change":-0.62,"latestTime":"09-11 16:00:00 EDT","open":158.27,"high":159.6607,"low":156.13,"amount":1324607084.0494199,"amplitude":0.022514,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":18.23,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":156.82,"sharesOutstanding":63325000,"nav":156.174274,"aum":10736981366.38,"dividendRate":0.003615,"bidAskSpread":0.000302,"preHourTrading":{"tag":"盘前","latestPrice":158.23,"preClose":156.82,"latestTime":"09:29 EDT","volume":40501,"amount":6393566.4319400005,"timestamp":1789133399999,"change":1.41,"changeRate":0.008991,"amplitude":0.013009},"postHourTrading":{"tag":"盘后","latestPrice":156.43,"preClose":156.2,"latestTime":"19:59 EDT","volume":555911,"amount":86836947.7522,"timestamp":1789171191129,"change":0.23,"changeRate":0.001472,"amplitude":0.001601},"volumeRatio":1.2777409531718278,"optionData":{"bulkOrders":[{"symbol":"XBI","call":false,"expireDate":1790308800000,"strike":"157.0","timestamp":1789148514638,"price":3.65,"volume":2865,"amount":1045725,"type":"+"},{"symbol":"XBI","call":false,"expireDate":1790308800000,"strike":"150.0","timestamp":1789148514638,"price":1.15,"volume":2865,"amount":329475,"type":"-"}]},"impliedVol":0.2874,"impliedVolPercentile":0.1554},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","floatShares":67375000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.2777409531718278,"shares":67375000,"dividePrice":0.5646,"high":159.6607,"amplitude":0.022514,"preClose":156.82,"low":156.13,"week52Low":92.64,"pbRate":"--","week52High":169.89,"institutionHeld":0.8511,"latestPrice":156.2,"eps":18.23,"divideRate":0.003615,"volume":8413893,"delay":0,"ttmEps":18.23,"open":158.27,"prevYearClose":121.93,"prevWeekClose":163.81,"prevMonthClose":162.5,"prevQuarterClose":158.25,"fiveDayClose":164.38,"twentyDayClose":156.86,"sixtyDayClose":135.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBI\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"XBI","amount":0.138094,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2025-12-22","symbol":"XBI","amount":0.406564,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XBI","amount":0.02665,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"},{"date":"2025-06-23","symbol":"XBI","amount":0.007295,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-25"},{"date":"2025-03-24","symbol":"XBI","amount":0.00525,"announcedDate":"2025-03-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBI\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-26","value":0.031139,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.01831,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.019702,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.110135,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.03704,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBI\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666533350","title":"北京生物醫藥保險共保體正式成立 完善創新醫藥產業保障","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533350","media":"央视新闻客户端","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533350?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:18","pubTimestamp":1788956280,"startTime":"0","endTime":"0","summary":"记者从北京市科委、中关村管委会了解到，北京生物医药保险共保体于近日正式成立，这是继全国首个商业航天保险共保体落地之后，北京在科技保险领域的又一重要实践。北京生物医药保险共保体的成立，将有效分散创新药械初创企业研发风险，也为投资机构分担投资不确定性，进一步引导更多社会风险资本投向创新药械管线的临床研究环节，打通金融支持生物医药成果转化的关键环节。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfums3623315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","XBI","399441","BK4588","161726","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104370787","title":"醫療保健板塊動態：市場快訊綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1104370787","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104370787?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:22","pubTimestamp":1788942151,"startTime":"0","endTime":"0","summary":"涵盖医疗保健板块的最新市场快讯，于美国东部时间4:20、12:20及16:50在道琼斯通讯社独家发布。该分析师表示，del-desiran原本是近期120亿美元收购Avidity的首个有力佐证。股价下挫4.7%，报2,251.0日元。2239 GMT——Petra Capital表示，由于美国食品药品监督管理局未对Echo IQ用于检测心力衰竭的工具EchoSolv HF给予批准，该公司股价今日可能遭遇抛售。FDA出具了“非实质性等同”判定。业界不乏企业在解决相关问题后最终获得FDA批准的案例。该机构将该股评级从“持有”下调至“卖出”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","XLV","XBI","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308646","title":"美股收盤：三大指數集體下跌，道指跳水重挫超600點；半導體、光通信逆市狂飆，英特爾升逾9%，Lumentum升逾11%；生物醫藥齊跌，科技普跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308646","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308646?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 06:40","pubTimestamp":1788907239,"startTime":"0","endTime":"0","summary":"美东时间周二（8日），美股三大指数因油价持续上涨走弱。截至收盘，道指跌1.18%，跌幅628.18点；标普500指数跌0.58%，纳指跌0.32%。大型科技股多数下跌，英伟达跌超2%，苹果、微软跌超1%，亚马逊、META小幅下跌；特斯拉涨近4%，谷歌微涨。费城半导体指数逆势涨1.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093868478416.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093868478416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TEKX","CHPS","XSD","SOXX","SMHX","SSG","SOXY","VUG","LYTE","DDM","FOTO","VGT","LEGR","PSI","VYM","EIS","DOG","DJIA","FWD","CNAV","INTC","FDN","DIA","LITE","SOXL","TOPT","TECY","USD","159582","CHPY","DVY","LINT","EGGY","SOXQ","XBI","SIXG","AIS","FDVV","399441","INTW","CWC","SMH","161726",".DJI","NBDS","FTXL","SOXS","LUMA","MQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196486882","title":"醫療保健板塊快訊：市場動態一覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1196486882","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196486882?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:57","pubTimestamp":1788901078,"startTime":"0","endTime":"0","summary":"聚焦医疗保健领域的最新市场快讯。本专栏内容仅通过道琼斯通讯社在美东时间4:20、12:20及16:50准时发布。受此消息影响，该公司股价应声下挫10%。这家美资投行认为，市场共识似乎低估了产品组合持续优化对利润率带来的积极影响。随着肾病药物Voyxact等自有资产逐渐接棒合作产品，成为这家日本制药企业的主要收入驱动力，Jefferies预测，在这一转型过程中，公司的利润增速将超越收入增速。为此，Jefferies将大冢的目标股价从12,700日元上调至14,000日元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4581","BK4585","XBI","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183339770","title":"摩根士丹利：Grindr醫療健康業務藴藏巨大商機","url":"https://stock-news.laohu8.com/highlight/detail?id=1183339770","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183339770?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:42","pubTimestamp":1788892936,"startTime":"0","endTime":"0","summary":"美东时间14:40——Grindr或将演变为一家披着约会应用外衣的医疗健康企业。该公司已借旗下Woodwork业务涉足远程医疗领域，该业务主要提供勃起功能障碍等病症的治疗药物。然而，摩根士丹利分析师在与Grindr管理层会晤后发布的研报中指出，Grindr的\"医疗健康雄心远不止于Woodwork\"。管理层认为，未来的健康相关收入机遇有望超越其核心业务规模。该公司正积极布局性传播疾病的预防与管理领域，并着眼于长远，旨在为平台用户提供全方位的临床医疗服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","BK4585","LU0528227936.USD","BK4127","BK4077","LU0106261372.USD","HCSG","LU1064131342.USD","KBWB","BK4504","LU2028103732.USD","LU1720051108.HKD","LABU","LU0158827948.USD","LU0029874061.USD","LU0314104364.USD","LU0795875086.SGD","LU1244550221.USD","LU1668664300.SGD","LU1988902786.USD","LU2023251221.USD","LU0971096721.USD","LU2089283258.USD","LU0795875169.SGD","BK4581","LU1720051017.SGD","LU1732800096.USD","LU0225283273.USD","LU1162221912.USD","LU0912757837.SGD","LU1989772840.SGD","LU2089284900.SGD","LU0210528500.USD","BK4516","LU0234570918.USD","LU0006306889.USD","LU0267386448.USD","LU0098860793.USD","LU1791710582.SGD","IAI","LU0158827781.USD","BK4588","LU2347655156.SGD","LU2357305700.SGD","LU1074936037.SGD","BK4534","LU1989772923.USD","SOCL","XBI","LU0106831901.USD","LU0882574139.USD","LU2111349929.HKD","LU2271345857.HKD","IE00BZ1G4Q59.USD","BK4137","LU0128526141.USD","IE00B3S45H60.SGD","LU1363072403.SGD","LU2133065610.SGD","LU1732799900.SGD","LU2487616109.SGD","LU0320765646.SGD","LU1791710400.SGD","MS","GRND","IE00BKVL7J92.USD","IE00B775SV38.USD","LU0390134368.USD","XLV","LU1244550494.USD","LU1244550577.SGD","LU0053666078.USD","LU1548497426.USD","LU0557290698.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112978991","title":"醫療保健板塊動態匯總：市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1112978991","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112978991?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 00:23","pubTimestamp":1788884589,"startTime":"0","endTime":"0","summary":"最新一期医疗保健板块市场快讯，涵盖行业动向与个股表现，于美国东部时间4:20、12:20及16:50通过道琼斯通讯社独家发布。该公司股价应声下跌10%。杰富瑞称，肾病药物Voyxact及其他自有资产正逐步取代合作产品，成为这家日本制药企业的主要收入驱动力。随着这一转型持续推进，该行预计利润增速将快于收入增速。杰富瑞将大冢目标价从12,700日元上调至14,000日元。该公司股价小幅上涨0.3%，报11,770日元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","XLV","XBI","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665753923","title":"Tenet Healthcare（THC）擬私募發行15億美元票據，置換到期債務","url":"https://stock-news.laohu8.com/highlight/detail?id=2665753923","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665753923?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:15","pubTimestamp":1788873326,"startTime":"0","endTime":"0","summary":"金吾财讯 | Tenet Healthcare（THC）周二公布债务操作计划，拟通过私募方式发行15亿美元、2034年到期的全新优先票据，用于对同等规模存量债务实施再融资。本次发行所得净资金，搭配公司现有现金，将全额赎回2027年11月到期，票面利率5.125%的优先有担保第一留置权票据。新票据属于无担保优先债务，和公司当前以及未来的其他无担保优先债务享有同等清偿顺位。本次票据发行还需要完成定价流程，并满足各类常规交割条件。票据仅依据相关证券豁免规则，面向合格机构投资者进行发售。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/MDE2NGUxYWJlMGQ4OGQwMTU5ZTY5YzEzNTY0MzU1Mzgx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MDE2NGUxYWJlMGQ4OGQwMTU5ZTY5YzEzNTY0MzU1Mzgx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305820","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","LU2324357040.USD","THC","BK4185","BK4585","XBI","LU0648000940.SGD","BK4581","XLV","LU1201861165.SGD","BK4588","LU0130103400.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378040","title":"HCW Biologics與Akron Biotech簽署獨家分銷協議，將HCW11-006作為試劑商業化，用於支持高功","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378040","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378040?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:50","pubTimestamp":1788871821,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","HCWB","BK4585","BK4581","BK4139","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665273123","title":"大家人壽9.8億元投資接力基金 後者投向硬科技、醫療健康等領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2665273123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665273123?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:25","pubTimestamp":1788866725,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IXJ","BK4585","BK4550","LABU","XBI","VHT","BK4581","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324454","title":"泰達生物(08189)與星辰通用簽署戰略合作框架協議 共同推動醫療健康具身智能技術體系、產品體系和解決方案的形成與產業化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324454","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324454?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:40","pubTimestamp":1788864000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物 公布，公司与湖南星辰通用机器人有限公司已签署战略合作框架协议。双方将本着平等自愿、优势互补、场景牵引、联合创新、资源共享、长期合作的原则，围绕医疗健康大模型与具身智能技术的深度融合，共同推动医疗健康具身智能技术体系、产品体系和解决方案的形成与产业化落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","BK1113","XBI","BK4588","LABU","XLV","159760","BK4585","08189","BK4550","WDRN","IXJ","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665654324","title":"英國藥品和醫療保健產品監管局已受理Biosplice公司關於洛雷西文特治療膝骨關節炎的申請，並正式啓動評估程序。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665654324","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665654324?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:33","pubTimestamp":1788863626,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4581","BK4550","XLV","BK4585","VHT","BK4588","LABU","CGVV","NOBL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169238098","title":"醫療保健板塊市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1169238098","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169238098?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:25","pubTimestamp":1788855909,"startTime":"0","endTime":"0","summary":"不过，分析师注意到，公司对2030年后实现中个位数百分比增长的雄心未作任何表态。杰富瑞认为，即便近期一款多发性硬化症口服新药取得了成功，但若缺少del-desiran和del-brax这两款自Avidity Biosciences收购而来的药物，要确立市场对公司2030年代增长前景的信心仍面临重重挑战。该公司股价下挫10%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LABU","XBI","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113703587","title":"港股生物醫藥股午後走強，劑泰科技-P漲近15%，百奧賽圖-B、金斯瑞生物科技漲近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113703587","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113703587?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:33","pubTimestamp":1788845625,"startTime":"0","endTime":"0","summary":"9月8日，港股$生物(000504)$医药股午后走强，$剂泰科技-P(07666)$涨近15%，$百奥赛图-B(02315)$、$金斯瑞生物科技(01548)$涨近10%，$泰格医药(03347)$、$康希诺生物(06185)$、$云顶新耀(01952)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000306701.USD","VXUS","BK1574","01548","07666","BK1583","BK1576","06185","HK0000320264.USD","BK1515","BK4581","BK0216","09939","BK4585","02315","03347","KCAI","BK4588","BK1141","688796","BK1191","XBI","01952","399441","161726","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166930636","title":"醫療保健板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1166930636","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166930636?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 04:52","pubTimestamp":1788814379,"startTime":"0","endTime":"0","summary":"1035 ET - 杰富瑞分析师指出，阿斯利康凭借其新药Ectamah正在开辟乳腺癌治疗的全新范式，该药刚刚获得美国食品药品监督管理局的上市许可。分析师们认为，这无疑是近年来乳腺癌领域最具分量的批准之一。尽管Ectamah的获批具有重大临床意义，但杰富瑞也提醒，目前其适用人群仅为全体乳腺癌患者中的一部分，这在短期内限制了其商业价值。该公司股价小幅上扬0.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4581","BK4588","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124637396","title":"醫療保健板塊市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1124637396","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124637396?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 00:22","pubTimestamp":1788798177,"startTime":"0","endTime":"0","summary":"1035 GMT——杰富瑞分析师指出，阿斯利康凭借其新药Ectamah，正在开启乳腺癌治疗的全新范式，该药物刚刚获得美国食品药品监督管理局的批准。分析师评价，这堪称近年来乳腺癌领域最具分量的审批之一。不过杰富瑞也提醒，尽管Ectamah获批在临床上意义重大，但目前其适用人群仅为全体乳腺癌患者中的特定亚群，这在一定程度上限制了其商业价值。该公司股价上涨0.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","XLV","XBI","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315217","title":"2070元/月，佛山這筆錢上調","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315217","media":"珠江时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665315217?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:00","pubTimestamp":1788775200,"startTime":"0","endTime":"0","summary":"随着佛山市最低工资标准9月1日失业金自待遇所属期2026年9月起上调至2070元/月。（二）享受的待遇标准1、失业保险金：按我市企业职工最低工资标准的90%按月发放，待遇所属期2026年9月起是2070元/月。大龄领金人员达到法定退休年龄时，或出现停止领取失业保险金情形的，停止享受由失业保险基金继续承担企业职工基本养老保险费。2025年2月1日及之后申请失业保险金的失业人员，按修改后的省条例执行，不再发放求职补贴。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-07/doc-iniqyzxu6360828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","XBI","BK4588","LABU","XLV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175448508","title":"醫療健康板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1175448508","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175448508?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:23","pubTimestamp":1788769386,"startTime":"0","endTime":"0","summary":"0727 GMT——CGS国际分析师Kasem Prunratanamala在研报中指出，Klinique医疗诊所上调了2026年营收指引，但这一利好消息似乎已被市场提前消化。这家医疗美容诊所运营商将2026年营收目标从41.5亿泰铢上调至45亿泰铢，理由是7月份现金销售增长强劲。尽管公司运营势头稳健，同店销售增长韧性十足，但近期股价的强势表现已充分反映了大部分正面消息。该券商维持该股\"持有\"评级及28.00泰铢的目标价。目前股价报29.00泰铢，上涨1.75%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XBI","BK4588","BK4585","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665962333","title":"從美妝到生物科技公司 植物醫生挺進大健康領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2665962333","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665962333?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 11:46","pubTimestamp":1788752760,"startTime":"0","endTime":"0","summary":"渠道红利退去、流量成本攀升、产品同质化加剧……中国美妆行业正经历从“快车道”到“窄门”的残酷转型。当“一招鲜”的战术红利消失，建立底层技术壁垒不再是可选项，而是生存项。当全行业 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260907/c679648733.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260907/c679648733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["159837","BK4585","MEDX","XBI","SYNB","AGNG","IBBJ","IEIH","HBImain","GDOC","BK4581","BK4588","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665954553","title":"人保健康保險大連分公司被罰27萬，涉聘任不合格人員等","url":"https://stock-news.laohu8.com/highlight/detail?id=2665954553","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665954553?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 10:47","pubTimestamp":1788749245,"startTime":"0","endTime":"0","summary":"蓝鲸新闻9月7日讯，近日，国家金融监督管理总局大连监管局发布行政处罚决定书，剑指中国人民健康保险股份有限公司大连分公司及相关责任人。罚单显示，中国人民健康保险股份有限公司大连分公司的主要违法违规行为是：聘任不具有任职资格的人员；编制、提供虚假的报告报表文件资料。针对上述违法行为，国家金融监督管理总局大连监管局对中国人民健康保险股份有限公司大连分公司罚款27万元；对傅信弘警告，罚款7万元；对周笑俊警告，罚款7万元；对刘志东警告，罚款1万元；对李翔警告，罚款4万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788746879733984657","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LABU","BK4585","BK4581","BK4588","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136673456","title":"醫療健康板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1136673456","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136673456?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 00:24","pubTimestamp":1788539073,"startTime":"0","endTime":"0","summary":"最新一期聚焦医疗健康领域的市场快讯已经发布，仅在道琼斯通讯社平台独家呈现，更新时段分别为美东时间凌晨4:20、中午12:20及下午4:50。分析师们认为，此项交易、上半年销售势头以及中国监管机构另行批准的进展，或将显著提升市场对和黄医药业绩指引的可见度。该公司预计2026年肿瘤学与免疫学领域收入将在3.3亿至4.5亿美元之间。目前该公司股价报22.60港元，涨幅为3.3%。以太坊上涨4.7%至2,506美元，瑞波币攀升7.4%至1.45美元，Solana则上涨4.8%至104.45美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XBI","BK4588","XLV","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}